Exane Derivatives’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Exane Derivatives’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,440	Closed	-$79.5K	–	739
2019 Q1	$79.5K	Buy	7,440 +4,414	+146%	+$47.3K	0.02%	319
2018 Q4	$26.5K	Buy	+3,026	New	+$38.5K	﹤0.01%	423

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exane Derivatives's SPPI Position: Q2 2019 in Review

Exane Derivatives sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2019, closing a stake of 7,440 shares — an estimated $79.5K sold.

Exane Derivatives first reported a position in SPPI in Q4 2018 and held it in 2 quarters. The position peaked at $79.5K in Q1 2019. 165 funds tracked by Wall St. Rank hold SPPI as of Q2 2019.

Exane Derivatives reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
Exane Derivatives sold 7,440 Spectrum Pharmaceuticals Inc shares in Q2 2019, an estimated $79.5K.
Exane Derivatives first reported a position in Spectrum Pharmaceuticals Inc in Q4 2018 and held it in 2 quarters.
Exane Derivatives's Spectrum Pharmaceuticals Inc position peaked at $79.5K in Q1 2019.
165 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2019.

Based on Exane Derivatives's 13F filing for Q2 2019, filed 12 Jul 2019.